Backed by a £680,000 grant from Leeds Hospitals Charity, the study is jointly led by academics and clinicians from the University of Leeds and Leeds Teaching Hospitals NHS Trust
The initiative aligns with global psycho-oncology standards that advocate routine distress screening as a core quality benchmark in cancer treatment
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
The deal gives Vertex access to Halozyme’s Hypercon technology for up to three drug targets
The results were consistent across both the 10 mg and 40 mg treatment arms
The partnership aims to accelerate clinical trial timelines, boost data quality, and improve decision-making for sponsors worldwide
The center combines rigorous scientific instruction with practical, hands-on training, equipping providers with the clinical, consultative, and business skills needed to deliver safe, effective, and patient-centered care
The trial also demonstrated significant improvements across multiple secondary endpoints
Subscribe To Our Newsletter & Stay Updated
